Seattle drug company had a good business year

Chetanya Robinson

Chetanya Robinson Jun 29, 2025

Jan 12, 2018

Republish Article

You can republish articles in print or online. Simply copy the HTML below, which includes our tracking pixel, all paragraph styles and hyperlinks, the author byline, and credit to Cascade PBS. Republishing of the photos or videos embedded in an article can occur only if the photo or video is a copyright of Cascade Public Media ("CPM") and not of a third party. Photos and videos that are a copyright of CPM are not required to appear in the republished article, but if they are used, they must be embedded where they appear in the original article and must include the attribution to the CPM photographer.

You may reprint in any medium
You may edit only for tense and timeliness
If republishing in print you can edit for length if you follow our print republishing guidelines.
You may write your own headline
Include a byline and shirttail with credit and link to Cascade PBS
Include our tracking pixel
Remove if we ask

          <article>
            <header>
              <hgroup>
                <h1>Seattle drug company had a good business year</h1>
                <h2><p>Seattle Genetics, a cancer drug company, had a successful fourth quarter and business year, primarily due to its growing sales of its drug Adcetris, according to the Puget Sound Business Journal. This drug — developed by Seattle Genetics in 2011 — earned the company $226 million in 2015, a 27 percent increase</p></h2>
              </hgroup>
               <p>By <a href="/author/chetanyarobinson-gmail-com/">Chetanya Robinson</a></p> 
              <p><time datetime="2025-02-04T05:00:00-08:00">Jan 12, 2018</time></p>
            </header>
            <p>Seattle Genetics, a cancer drug company, had a successful fourth quarter and business year, primarily due to its growing sales of its drug Adcetris, according to the <a href="http://www.bizjournals.com/seattle/blog/health-care-inc/2016/02/seattle-genetics-revenue-jumps-as-cancer-drug.html?ref=dev.cascadepbs.org">Puget Sound Business Journal</a>. This drug — developed by Seattle Genetics in 2011 — earned the company $226 million in 2015, a 27 percent increase from the $178 million earned the previous year.</p><p>However, the company also saw a loss of $120 million for the year.</p><p>Seattle Genetics develops antibody-based cancer drugs. These drugs have a wide reach: Adcetris, which is used to treat two types of lymphoma, is approved in 55 countries around the world. Seattle Genetics announced last week that <a href="http://www.bizjournals.com/profiles/company/jp//osaka/takeda_pharmaceutical_company_limited/3008999?ref=dev.cascadepbs.org">Takeda Pharmaceutical Co.</a> will pay Seattle Genetics $20 million in royalty fees for the sale of Adcetris after reaching a sales milestone. Takeda handles Adcetris sales outside the U.S. and Canada.</p>
          </article>

Seattle Genetics, a cancer drug company, had a successful fourth quarter and business year, primarily due to its growing sales of its drug Adcetris, according to the Puget Sound Business Journal. This drug — developed by Seattle Genetics in 2011 — earned the company $226 million in 2015, a 27 percent increase from the $178 million earned the previous year.

However, the company also saw a loss of $120 million for the year.

Seattle Genetics develops antibody-based cancer drugs. These drugs have a wide reach: Adcetris, which is used to treat two types of lymphoma, is approved in 55 countries around the world. Seattle Genetics announced last week that Takeda Pharmaceutical Co. will pay Seattle Genetics $20 million in royalty fees for the sale of Adcetris after reaching a sales milestone. Takeda handles Adcetris sales outside the U.S. and Canada.

Our members' donations make local journalism happen.

Support once for $1

Support monthly for $7

Cascade PBS Passport
Mossback members-only newsletter
Monthly Viewer Guide

Support monthly for $25

Invitation to quarterly news and original programming video conference
Annual in-person meet-up with news & programming teams
Special event perks (reduced price or free tickets, cocktails, etc.)

Continue

By Chetanya Robinson

Chetanya Robinson is a former intern with Crosscut. He was born and raised in Seattle and graduated from the University of Washington in fall 2016. He enjoys reporting on an eclectic range of topics,